Isosceles has assembled a team with decades of experience in successfully developing FDA-approved parenteral pain products from intravenous and surgical site injectables to transdermal patches and sublingual tablets. Our team has a singular focus: to create a rapid onset non-opioid/non-NSAID product with fast onset and long acting analgesia.
Brett J. Lanier
Brett Lanier is a medicinal chemist with over a decade of experience in the pharmaceutical industry and a founding member of Isosceles Pharmaceuticals. His background includes extensive knowledge around the chemical synthesis and pharmaceutical scale GMP manufacturing of synthetic Cannabinoids and controlled substances. He has worked within the medical device, clinical research, and pharmaceutical contract manufacturing industries with branded and 505(b)(2) branded generic customers at all levels of drug development from pre-formulation, early and late phase trials, and commercial launch post FDA approval.
Herbert Neuman MD, MBA
Chief Medical Officer
Drawing on his almost 20 years of experience in the pharmaceutical industry, Dr. Neuman provides consulting advice in the areas of medical affairs, new product development, launch strategies, pharmacovigilance, and business development. Board-certified in Internal Medicine, Dr. Neuman still practices medicine on a part time basis. During the course of his pharmaceutical career, he held a variety of senior executive positions, including Vice President of Global Regulatory Affairs, Vice President of Medical Affairs and Chief Medical Officer for a Fortune 500 global healthcare company. Throughout these roles, he successfully led efforts to gain both regulatory approval and clinician acceptance of multiple products, including pharmaceuticals, medical devices and imaging diagnostics.
Deborah Mosca, PhD
Chief Strategy Officer
Deborah Mosca is a proven leader of multi‐disciplinary drug development project teams with the ability to anticipate risks and implement creative solutions to meet project timelines and budgets. She has guided the discovery and development of novel therapeutic agents for human, animal, and agricultural applications in various organizations including biotech, non-profit research institutions, and large Pharma. In her previous role as Chairman and Chief Executive Officer of the Marine Bio-Technologies Center of Innovation, Deborah was responsible for creating the business strategy to drive the commercialization of marine biotechnologies from North Carolina's vast network of premier marine research institutions. At PaxVax, she provided strategic leadership for vaccine development programs and assisted with revenue generation through contracts, licensing, corporate partnerships, and venture capital activities. While at The Scripps Research Institute, Deborah coordinated efforts for the IBM-TSRI Consortium for Project Checkmate (a proactive approach to avian flu) and joined Governor Jeb Bush in meetings with Roche and Novartis to stimulate international economic development in Florida.
Mark A. Mannebach, PhD, RPh
Regulatory Affairs Strategy
Mark Mannebach has over 30 years of experience in the pharmaceutical industry in Regulatory Affairs with extensive knowledge of Quality Assurance, Program Management, and Pharmaceutical Science. During his career, he has filed numerous NDA’s, BLA’s, PME’s, ANDA’s and 505(b)(2) submissions. Mark has assisted with the development of branded and specialty pharmaceuticals as well as biologics for many therapeutic applications including ophthalmology, pain management, neurology/CNS, and anti-inflammation.
Clinical Affairs Specialist
Rebecca Johnson is an accomplished scientific professional on the verge of completing her PhD in Pharmaceutical Sciences, specializing in Chemical Biology and Medicinal Chemistry, from the University of North Carolina Eshelman School of Pharmacy. Her graduate journey has yielded numerous contributions to drug discovery and development efforts, including several publications and presentations at local and national meetings. Rebecca's expertise in the advancement and communication of scientific discoveries is exemplified by her success in securing funding through the esteemed National Science Foundation Graduate Research Fellowship and recognition of a best poster presentation award. Rebecca is committed to leveraging her background in drug discovery to help advance scientific breakthroughs into clinical applications.
Board of Directors
Executive Chairman of the Board
Tim Wright is a highly accomplished executive with a 30-year track record of building, transforming and positioning pharmaceutical organizations for continued growth across highly competitive markets. A visionary, focused leader recognized for creating value and improving quality of life leveraging his extensive experience in pain management and inflammatory diseases. Wright has achievements leading full lifecycle development of novel therapeutic modalities, from conception through commercialization and growth across North America, Europe and Asia.
Dr. Robert B. Stein, MD, PhD
Senior Medical Advisor & Board Member
Robert Stein, a Duke University Graduate School alumni, has a strong background in a wide ranging expertise from drug discovery, clinical research, development and trials in biopharmaceuticals and oncology. Robert served as Executive Director and Head of Pharmacology at Merck Sharp & Dohm, SVP of R&D and CSO for Ligand Pharmaceuticals, and EVP of Research & Pre-Clinical Development Dupont-Merck Pharmaceuticals. He also served as President of Incyte, Roche and CEO of KineMed, Inc. as well as a Senior Advisor of R&D at Agenus, Inc. and is an Operating Partner at Samsara BioCapital.
Mr. Devin Bosch founded Capital Group in 2004, a successful business strategy and venture firm. With over 50 liquidity driven events, Capital Group became internationally recognized with multiple offices in San Francisco, the Bay Area, and Charlotte, NC. In 2008, Mr. Bosch co-founded Nuwa Ventures, a family office located in Walnut Creek, CA.
Kevin Fickle is an entrepreneur with extensive capital markets experience in the technology and consumer goods verticals. He has worked at multiple private equity firms, where he has held responsibilities including overseeing the operational strategy and capital markets activities of its funds’ portfolio companies. In 2008, he co-founded Nuwa Ventures, a family office where he is responsible for originating, structuring, and analyzing portfolio investments, and has served as its President since its founding. Mr. Fickle received a B.S. in Finance from San Diego State University.
William Humphries, MBA
William Humphries is an exceptional leader that embodies the ability to develop and implement overall strategies to deliver results. High performing and experienced executive professional with more than 33 years of background and knowledge leading specialty pharmaceutical industry companies as President of Ortho-Dermatologics (a Bausch Health Company), Chief Executive Officer at Merz, President at Stiefel (a GSK company), and Vice President Sales and Marketing at Allergan. He brings to Isosceles significant business acumen and the ability to manage high levels of stress without comprising judgment in key decision-making activities.
Dr. Michael Giuliani, MD
Medical and Clinical Advisor
Michael Giuliani is 30+ year drug development physician with over one hundred new market authorizations for eighteen different products spread across a total of 60 different countries. He was involved with the development of a number of different FDA approved pain therapies and anti-inflammatory drugs including Zipsor, Pennsaid 1.5/2.0 %, Exalgo, Xartemis XR, Topiramate, Neurontin, Pregabalin and a generic Fentanyl Transdermal System (FTS) Patch. His positions included Chief Medical Officer at Xanodyne Pharmaceuticals, Head of R&D at Mallinckrodt Pharmaceuticals as well as positions at Merck, Wyeth and Covidien. Dr. Giuliani has authored dozens of peer reviewed scientific publications, chapters, and abstracts. He was involved in due diligence, in-licensing, out-licensing, and investor interaction activities at Merck, Xanodyne, Covidien, and Mallinckrodt Pharmaceuticals.
Thomas L. Harrison, LH.D.
Mr. Harrison is Chairman Emeritus of the Diversified Agency Services (DAS) division of Omnicom Group Inc., having served as its President, then Chairman and CEO. During his 17-year tenure, DAS became the world’s largest holding company of innovative, entrepreneur-led marketing services companies, including national advertising agencies, specialist PR companies, crisis management, branding/design, sales promotion/CRM, talent procurement, and highly strategic, clinically-focused companies competing in the healthcare/wellness industry sectors. He co-founded The Harrison & Star Business Group, comprised of companies in the healthcare, wellness, medical education, and healthcare public relations industries, representing many of the largest and most well-known pharmaceutical companies and biotech companies. Mr. Harrison currently serves on a number of prestigious boards including the Montefiore Health System and Madison Logic, and previously served on the board of Zynerba Pharmaceuticals and as a Fellow of the New York Academy of Medicine and member of The New York Academy of Sciences. He is a recipient of the Ellis Island Medal of Honor and has received an Honorary Doctorate from West Virginia University where he earned a graduate degree in cell biology and physiology. He is the author of "INSTINCT, Tapping Your Entrepreneurial DNA to Achieve Your Business Goals." and has appeared on CNBC, CNN, Bloomberg, and Forbes.com
Hunter Land, MS
Hunter Land, MS is the Vice President, Translational Research at Biopharmaceutical Research Company and Executive Board Member at Alterola Biotech, Inc. He has more than 20 years of R&D expertise across 25 different indications, as well as 10 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Hunter acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation, the world’s largest cannabis producer. Most notably, Hunter was GW Pharma’s first full time employee within R&D in the US, where he co-authored multiple protocols in refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), Multiple Sclerosis, pain, and was closely involved in the clinical development of Epidiolex® (FDA approved prescription CBD) and Sativex®. He has been a speaker at over 50 scientific conferences, a named inventor on 6 patent applications, has over 20 publications, and is a guest lecturer at the University of Wisconsin and Colorado State University. He has been featured in various magazines including Forbes and Entrepreneur as a cannabinoid subject matter expert. Hunter is the Sr. Scientific Advisor for the NHL Alumni/NEEKA Brain Health, co-founder of the Cannabinoid Education Working Group, a scientific board member of Veterinary Cannabis Society, and sits on the advisory board for the Council for Federal Cannabis Regulation.
Dr. Mike A. Royal, MD, JD, MBA
Mike Royal is a senior pharmaceutical executive with over 30 years’ experience in the drug development process with expertise in clinical research and medical and regulatory affairs. He has been responsible for clinical trial oversight from phase 1 through phase 4, including multi-site/multi-country trials and has an established track record for innovative solutions to development obstacles. Mike has been instrumental in setting product launch and lifecycle management strategies and successfully submitted NCE and 505(b)(2) NDAs across several indications as well as ANDAs. He is board-certified in internal medicine, anesthesiology, pain management and addiction medicine and has over 190 peer-reviewed publications, book chapters and abstracts/posters.